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نقيلة العضلة اهليكلية من سرطان اخلاليا الكلوية
21 حالة ومراجعة الدراسات املنشورة
متارا منري هايجود، حممد �سيوح، جي�سون ووجن، جينفر لني، اآيريليو ماتامورو�س، كارل �ساندلر، جون مادويل
abstract: Objectives: This study aimed to raise radiologists’ awareness of skeletal muscle metastases (SMM) in 
renal cell carcinoma (RCC) cases and to clarify their imaging appearance. Methods: A retrospective analysis was 
undertaken of 21 patients between 44–75 years old with 72 SMM treated from January 1990 to May 2009 at the 
MD Anderson Cancer Center in Houston, Texas, USA. Additionally, 37 patients with 44 SMM from a literature 
review were analysed. Results: Among the 21 patients, the majority of SMM were asymptomatic and detected 
via computed tomography (CT). Mean metastasis size was 18.3 mm and the most common site was the trunk 
muscles (83.3%). The interval between discovery of the primary tumour and metastasis detection ranged up to 234 
months. Peripheral enhancement (47.1%) was the most common post-contrast CT pattern and non-contrasted 
CT lesions were often isodense. Magnetic resonance imaging (MRI) characteristics were varied. Five lesions with 
available T1-weighted pre-contrast images were hyperintense to the surrounding muscle. Other organ metastases 
were present in 20 patients. Of the 44 SMM reported in the literature, the majority were symptomatic. Average 
metastasis size was 53.4 mm and only 20.5% of SMM were in trunk muscles. The average interval between 
tumour discovery and metastasis detection was 101 months. Other organ metastases were recorded in 17 out 
of 29 patients. Conclusion: SMM should always be considered in patients with RCC, even well after primary 
treatment. SMM from RCC may be invisible on CT without intravenous contrast; contrast-enhanced studies are 
therefore recommended. SMM are often hyperintense to the surrounding muscle on T1-weighted MRI scans.
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الكلوية  اخلاليا  �رسطان  حالت  يف  الهيكلية  الع�سلة  نقيلة  عن  الأ�سعة  اأخ�سائي  وعي  زيادة  اإىل  الدرا�سة  هذه  تهدف  الهدف:  امللخ�ص: 
وتو�سيح مظاهر �سورها الأ�سعاعية. الطريقة: مت اإجراء حتليل اإ�ستعادي على 21 مري�سا اأعمارهم بني 75-44 �سنة لديهم 72 حالة معاجلة 
لنقيلة الع�سلة الهيكلية من يناير 1990 اإىل مايو 2009 يف مركز اأندر�سون لل�رسطان يف هيو�سنت، تك�سا�س، الوليات املتحدة الأمريكية. 
بال�سافة اإىل ذلك، مت حتليل 37 مري�سا لديهم 44 حالة نقيلة الع�سلة الهيكلية من الدرا�سات املن�سورة. النتائج: من بني 21 مري�سا، كان 
معظم �رسطان اخلاليا الكلوية عدمي الأعرا�س ومت ك�سفه عن طريق الأ�سعة املقطعية. متو�سط مقا�س النقيلة كان 18.3 ملم وكان اأكرث موقع 
�سيوعا هو الع�سالت اجلذعية )%83.3(. الفرتة بني اكت�ساف املر�س الأويل وك�سف النقيلة امتدت اإىل 234 �سهرا. ا�ستعزاز احلافة )%40( كان 
اأكرث الأمناط �سيوعا يف الأ�سعة املقطعية املتباينة، وكانت الآفات عادة بذات الكثافة يف الأ�سعة املقطعية املتبانية. خ�سائ�س الت�سوير 
بالرنني املغناطي�سي كانت متعددة. خم�سة اآفات كانت مفرطة الكثافة مقارنة بالع�سالت املحيطة يف ال�سور املوزونة T1 قبل التباين. 
الأدبيات، كان مع�سمها  املن�سورة يف  الهيكلية  الع�سلة  نقيلة  44 حالة  20 مري�سا. من بني  كانت موجودة يف  الأخرى  الأع�ساء  نقيلة 
عر�سية. متو�سط مقا�س النقيلة كان 53.4 ملم و %20.5 من النقيلة كانت يف الع�سالت. اجلذعية متو�سط الفرتة بني اأكت�ساف الورم وك�سف 
النقيلة كانت 101 �سهرا. نقيلة الأع�ساء الأخرى كانت م�سجلة يف 17 من اأ�سل 29 مري�سا. اخلال�صة: نقيلة الع�سالت الهيكلية يجب اأن توؤخذ 
يف العتبار يف مر�سى �رسطان اخلاليا الكلوية، حتى بعد مرحلة العالج الأويل. نقيلة الع�سلة الهيكلية من �رسطان اخلاليا الكلوية رمبا 
تكون غري مرئية يف الأ�سعة املقطعية بدون التباين الوريدي، لذا يو�سى بدرا�سات ا�ستعزاز التباين. نقيلة الع�سلة الهيكلية عادة مفرطة 
.T1 الكثافة مقارنة بالع�سلة املحيطة يف ت�سوير الرنني املغناطي�سي  املوزونة
مفتاح الكلمات: �رسطان اخلاليا الكلوية؛ الع�سلة الهيكلية؛ نقيلة؛ الوليات املتحدة الأمريكية.
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Advances in Knowledge
- The findings of this study suggest that relatively small and asymptomatic skeletal muscle metastases of the trunk in patients with renal cell 
carcinoma (RCC) are usually detected by re-staging computed tomography (CT).
- Furthermore, skeletal muscle metastases among the studied RCC patients were often hyperintense to the muscle on pre-contrast T1-
weighted magnetic resonance images and invisible or barely visible on CT images without contrast.
- A marked male predominance was observed among the studied RCC patients with skeletal muscle metastases.
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Renal cell carcinoma (RCC) comprises nearly 90% of all malignant renal neoplasms and the metastatic potential of this cancer 
is widespread and unpredictable.1 While metastasis 
to the skeletal muscles is considered unusual, RCC 
is among the more common primary tumours to 
metastasise to this type of muscle tissue.2–5 In a review 
of over 2,000 patients with metastatic solid tumours, 
Surov et al. found that 2.3% of those with RCC had 
skeletal muscle metastases.6 The location of skeletal 
muscle metastases can vary widely. Furthermore, they 
may be painless and can sometimes occur long after 
the primary surgical treatment; therefore, discovering 
these metastases can be challenging. In order to 
reduce the chance of overlooking muscle metastases, 
the possibility of their presence should be considered 
in patients with a history of RCC, even long after the 
primary tumour has been resected.7 
Methods
A retrospective analysis was undertaken of 21 patients 
between 44–75 years old with 72 skeletal muscle 
metastases treated from January 1990 to May 2009 
at the MD Anderson Cancer Center in Houston, 
Texas, USA. Demographic, diagnostic, clinical and 
radiological data and patient outcome information 
were collected from teaching files and retrospectively 
reviewed and analysed. Cases were reviewed with 
regard to age; gender; presenting symptoms; time of 
diagnosis; histopathological subtype of the primary 
tumour; time of initial discovery of the skeletal muscle 
metastases; first time the muscle metastases were 
visible on retrospective review; evidence of skeletal 
muscle and other metastases; and patient outcome. 
Skeletal muscle tumours seemingly caused by the 
direct extension into the skeletal muscles of the cancer 
from the kidneys or from other metastases were not 
included. Only metastases presumed to have spread 
haematogeneously were included in the analysis. 
Diagnoses were made from clinical, pathological and 
radiological data.
Images from computed tomography (CT) and 
magnetic resonance imaging (MRI) from the time the 
skeletal muscle metastases were first reported were 
examined by two radiologists to evaluate the site, size, 
shape, CT density and MRI characteristics (including 
MRI signal intensity, pattern of enhancement and 
any other special features) of the metastases. In some 
cases, individual skeletal muscle metastases were 
never mentioned in the radiological reports. In these 
cases, the radiologists determined the earliest imaging 
study on which the metastases were visible. When 
additional skeletal muscle metastases appeared after 
the initial discovery, up to eight lesions per patient 
were also included in the analysis. When more than 
eight muscle metastases were present, the largest eight 
lesions were evaluated. MRI signal intensity and CT 
density were compared with those of the adjacent 
muscles. Imaging characteristics were determined by 
consensus between the two radiologists. 
Additionally, a literature review was also conduct-
ed to include 37 patients with 44 skeletal muscle 
metastases in the analysis. Journal articles for the 
literature review were identified by searching the 
MEDLINE®/PubMed database for articles containing 
the words “metastasis” and “muscle” in the title. Other 
relevant articles cited in the bibliographies of these 
articles were also included. The literature review 
was limited to articles published in English, French 
or German. The cut-off point for the review was 
March 2013. 
This study was performed in accordance with 
institutional policies and approved by the Institutional 
Review Board of The University of Texas, MD 
Anderson Cancer Center. 
Results
The demographic characteristics and CT imaging 
characteristics of the muscle metastases for the 21 
patients studied are shown in Table 1. Nine of these 
patients had previously been reported in less detail by 
Haygood et al. in 2012;5 however, the other 12 had not 
been studied previously. The average age of the patients 
at the time of discovery of the first skeletal muscle 
metastasis was 58.1 years (range: 44–75 years). Only 
three of the patients were women and the rest were 
men. In 17 of the patients (81.0%), the histopathological 
subtype of the primary RCC was conventional clear 
cell RCC, with Fuhrman nuclear grades ranging from 
2–4 (45.5% of the lesions were grade 3). There was one 
case of chromophobe RCC. In the remaining three 
patients, the primary tumours had been diagnosed at 
outside institutions and it was impossible to confirm 
the subtype of the original tumour. 
Application to Patient Care
- As indicated by the results of this study, radiologists interpreting re-staging CT scans of patients with RCC should be alert for signs of possible 
muscle metastases.
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Table 1: Demographic characteristics, outcomes and tumour conditions of skeletal muscle metastases as assessed by 














49/M 36 Died after nine months Paraspinal 5 x 5 Isodense Homogeneous 
50/M Presenting sign Alive with minimal 
disease
Deltoid 40 x 37 Hypodense N/A


















62/M 28 Died after 46 months Paraspinal 8 x 7 N/A Homogeneous








52/M 44 Died after 13 months Psoas 47 x 35 Hypodense Peripheral



































































63/M 234 Died after 13 months Paraspinal 11 x 8 Isodense Homogeneous
71/M 6 Died after two months Psoas 60 x 56 Isodense Heterogeneous
66/F 12 Died after 37 months Intercostal 27 x 24 Isodense Peripheral
63/M 2 Died after four months Gluteal 13 x 7 N/A Homogeneous
75/F 31 Died after 
approximately 42 
months or later
Gluteal 30 x 17 N/A Peripheral
58/M 25 Alive with minimal 
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A total of 72 muscle metastases in this patient 
group were analysed, with smaller metastases in two 
patients with more than eight metastases excluded. 
Of these, 60 (83.3%) were in trunk muscles (including 
the pectoralis major), nine (12.5%) were in muscles 
of the upper extremities, two (2.8%) were in muscles 
of the lower extremities and one (1.4%) was in the 
tongue. Most of these metastases were asymptomatic 
and discovered via CT. Two patients complained of a 
painful swelling at the metastasis site and one reported 
a painless, palpable swelling. In one patient, the muscle 
metastasis was the initial presenting complaint. 
The time interval between the discovery of the 
primary tumour and the discovery of the skeletal 
muscle metastases varied. Skeletal muscle metastasis 
was the presenting complaint for one patient 
and skeletal muscle metastases were omitted in 
radiological reports for another patient. Two patients 
had had RCC nine and 19 years before subsequently 
presenting with metastatic disease and a mass in the 
previously unaffected kidney. In the first of these latter 
two patients, the new renal mass was relatively large 
compared with the other masses and it was judged to 
be a new primary tumour. For the second patient, the 
new renal mass was distinctly smaller than several of 
the other masses, so it was judged to be a metastasis 
from the previous cancer. Including these four patients, 
and with the discovery of the originally unreported 
metastases considered to have occurred when they 
were identified on retrospective review, the interval 
between the discoveries of the primary tumour and 
the skeletal muscle metastasis ranged from 0–234 
months (average interval: 32 months). Excluding these 
four patients, the interval between discoveries ranged 
from 2–75 months (average interval: 25 months). 
Metastasis to the skeletal muscles was proven by 
direct biopsy in three patients. Among the remaining 
18 patients, 13 had pathology-evidenced metastatic 
RCC in other locations and five had clinical and 
radiological evidence of metastasis to other organs 
typical of RCC. The mean size of the muscle metastases 
at the time they were reported (or when first visible, 
if not reported) was 18.3 mm in the greatest axial 
dimension (range: 2–113 mm). The average size 
of those that were asymptomatic at discovery was 
16.3 mm. 
A total of 39 lesions (54.2%) were oval [Figure 1], 16 
(22.2%) were round, 15 (20.8%) were irregular and two 
(2.8%) were lobular. CT images without intravenous 
contrast were available for 29 lesions, nearly two-
thirds of which (n = 19; 65.5%) were isodense to the 
adjacent muscle. Of 69 lesions with contrast-enhanced 
CT images, enhancement on post-contrast CT was 
homogeneous in 20 (29.0%), heterogeneous in 16 
(23.2%) and peripheral in 33 (47.8%) [Figure 2]. Six 
patients had MRI examinations. All lesions with T2-
weighted images demonstrated hyperintense signals. 
Five of the seven lesions with available T1-weighted 
pre-contrast images were hyperintense [Figure 3]. 
Although contrast enhancement was variable, all 
50/F 37 Died after 11 months Latissmus dorsi 20 x 15 Isodense Homogeneous
























62/M 6 Died after five months Psoas 11 x 9 Isodense Peripheral








































M = male; F = female; N/A = not available.
*At the time the skeletal muscle metastases were first discovered or, if not reported, at the time the metastases first became visible on imaging. †Interval 
between the primary tumour and the discovery of the first skeletal muscle metastasis. ‡Perpendicular measurements on the axial image in which 
the lesion appeared largest. Measurements were made using electronic callipers. §The surrounding muscle is the reference standard for computed 
tomography density. For some patients, there were no images available without contrast. ¶One lesion was isodense to the muscle with contrast, so it is 
unclear whether it was enhanced. Heterogeneous enhancement means that the lesion was enhanced in a patchy fashion throughout its substance and 
not just around the periphery. //Interval between the primary tumour and when the muscle metastases were visible in retrospect.
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lesions showed enhancement. Small enhancing vessels 
feeding or draining the skeletal muscle metastases were 
noticed in five (7.2%) of the lesions for which contrast-
enhanced CT was available [Figure 4]. Surrounding 
muscle oedema was seen in one case. No calcification 
was found in or around any of the lesions. 
All but one of the patients with muscle metastases 
had metastases to other organs at the time the muscles 
metastases were discovered. These metastases occur-
red mainly in the lungs (85.7%), liver (28.6%), bones 
(33.3%) and brain (23.8%). The exception was the 
patient whose muscular metastasis was the presenting 
complaint; this patient was noted to have pulmonary 
nodules on a CT scan eight months after presentation.
Of the 20 patients for whom follow-up informat-
ion was available, 18 have died to date. One patient, 
who presented with very advanced disease and 
metastases in multiple organs, died within one 
month of the discovery of the muscle metastases. The 
other 17 patients survived for between 2–52 months 
(average: 21 months). At the time of writing, two 
patients remained alive with minimal disease, one of 
whom had survived for more than five years after the 
discovery of the muscle metastases. 
The literature review revealed 36 case reports 
detailing 37 cases of RCC metastasis to the skeletal 
muscles [Table 2].2,3,7‒40 There were 19 other patients 
reported in the literature; however, insufficient 
information was given regarding individual cases and 
 
Figure 1A–D: Enhanced computed tomography (CT) images of a 58-year-old man with renal cell carcinoma. A: Initial 
detection and reporting of a left trapezius metastasis measuring 14 x 11 mm (arrow). B: The same metastasis was subtler 
and less well-defined yet still visible 11 months earlier (arrow). This lesion had a heterogeneous pattern of enhancement. 
C: Initial detection and reporting of a left paraspinal metastasis measuring 10 x 9 mm (arrow). D: The same metastasis 
was much smaller although still visible 11 months earlier (arrow). This lesion had a homogeneous pattern of enhancement 
when first visible which became peripheral later. Both muscle metastases appeared oval when they were first detected in 
cross-sectional imaging.
 
Figure 2: Contrast-enhanced computed tomography 
image of a man with renal cell carcinoma and left 
gluteus medius muscle metastasis showing peripheral 
contrast enhancement (arrow).
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lower extremities and seven (16.3%) were in muscles 
of the head and neck.2,7‒40 The majority of the skeletal 
muscle metastases in the literature were symptomatic. 
Only six patients had skeletal muscle metastases that 
were discovered incidentally on imaging.7,16,18,23,29,37 
In seven reports, the muscle metastasis was the 
initial presenting complaint.3,8,21,24,27,28,32 Skeletal muscle 
metastasis was found synchronously with the primary 
tumour in two cases.29,37 There was no information 
regarding the time interval between the discovery 
of the primary tumour and discovery of the muscle 
metastasis in five cases.9,11,26,34 For the remaining 23 
cases, the interval ranged from 6–252 months (average: 
101 months).2,7,10,12–20,22,23,25,30,31,33,35,36,38–40 The average 
size of the skeletal muscle metastases at presentation, 
available for 28 of the lesions reported in the literature 
these were therefore not included in the analysis.4,8,9 
The average age of the patients from the literature 
review at the time of the first skeletal muscle metastasis 
discovery was 61.9 years (range: 41–81 years). There 
were five women and 31 men. The age and gender of 
one patient was not specified.34 In 18 (81.8%) of the 
22 cases for which the histopathological subtype was 
available, the primary tumour was conventional clear 
cell RCC.7,10,13,15,16,18,20‒24,27,28,32,35,37,38,40 There was one case 
each of granular cell and sarcomatoid RCC.31,39 
A total of 44 metastases in these 37 literature 
review cases were analysed, although the information 
available for each varied. Of the 43 lesions for which 
the location site was available, nine (20.9%) were 
in trunk muscles, 11 (25.6%) were in muscles of the 
upper extremities, 16 (37.2%) were in muscles of the 
 
Figure 3A & B: Magnetic resonance imaging (MRI) of a 49-year-old man with renal cell carcinoma. A: Post-contrast 
fat-saturated T1-weighted axial MRI scan at the L2 level showing a small metastasis in the right paraspinal musculature 
that is enhanced brightly. B: Pre-contrast T1-weighted axial MRI scan at the same level shows that this small metastasis 
is hyperintense to the surrounding muscle (arrow). 
 
Figure 4A & B: Contrasted computed tomography images from a 44-year-old man with renal cell carcinoma showing 
muscle metastasis with visible feeding or draining vessels in the left quadriceps (arrows). This is also an example of a 
heterogeneous pattern of enhancement.
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Table 2: Demographic characteristics, outcomes and tumour conditions of skeletal muscle metastases in selected 
renal cell carcinoma patients reported in the literature (N = 37)
Author and year of report Cases Age in years/gender Interval in 
months†
Site Size in 
mm
Chen et al.2 2005 1 50/M 168 Vastus medialis 50 x 40
Herring et al.3 1998 1 62/M Presenting sign N/A N/A
Sakamoto et al.7 2007 1 65/M 72 Gluteal muscles N/A
Capone et al.8 1990 1 63/M Presenting sign Extraocular muscles* N/A
Pretorius et al.9 2000 1 73/F N/A Deltoid* N/A
Nabeyama et al.10 2001 1 81/M 180 Triceps brachii 
Brachioradialis
40 x 30 
10 x 10
















Lee et al.12 2008 1 81/M 60 Thigh 50
Hur et al.13 2007 1 63/M 228 Psoas 
Vastus medialis
28 x 19 
N/A
Pompo et al.14 2008 1 73/M 252 Biceps femoris 160 x 75
Nakagawa et al.15 1996 1 57/M 48 Masseter 10
Taira et al.16 2005 1 63/M 168 Psoas 15
Munk et al.17 1992 1 57/M 8 Trapezius 70 x 40
Linn et al.18 1996 1 58/M 168 Psoas 50
Judd et al.19 2000 1 72/F 60 Deltoid 100 x 80
Manzelli et al.20 2006 1 73/F 96 Quadriceps 
Sartorius 
Adductor magnus
90 x 50 
35 
30
Alexiou et al.21 1984 1 74/M Presenting sign Arm muscles 65 x 60
Alimonti et al.22 2003 1 62/M 6 Deltoid 30
Camnasio et al.23 2010 1 63/M 132 Psoas 18
Chandler et al.24 1979 1 62/M Presenting sign Biceps 100 x 80
Di Tonno et al.25 1993 1 55/M 144 Gluteal muscles 47
Egund et al.26 1981 1 60/F N/A Shoulder muscles Large
Gal et al.27 1997 1 49/M Presenting sign Masseter 40 x 40
Gözen et al.28 2009 1 58/M Presenting sign Gastrocnemius 40 x 20
Hyodo et al.29 2009 1 65/M Synchronous Infraspinatus N/A
Kang et al.30 2010 1 71/M 144 Temporalis 41
Karakousis et al.31 1981 1 63/M 69 Thigh muscles N/A
Kishore et al.32 2006 1‡ 42/M Presenting sign Shoulder muscles 80 x 70
Merimsky et al.33 1990 1 69/M 12 Biceps femoris 
Gluteal muscles
N/A
Peyster et al.34 1987 1 N/A N/A Extraocular muscles N/A
Picchio et al.35 2010 1 58/M 60 Adductor magnus 50
Ruiz et al.36 1991 1 63/F 192 Vastus lateralis N/A
Sano et al.37 2007 1 53/M Synchronous Paraspinal muscles 150
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normally examined in CT scans of the chest, abdomen 
and pelvis. The sites of involvement among the study 
cohort predominantly involved the trunk muscles; 
this was similar to findings from other research.5,42 
Surov et al. studied a large group of patients with 
muscle metastases of all types.43 They found a larger 
representation of metastases in the extremities and 
extraocular muscles, likely because the study included 
both patients from their own institution and those 
from previous publications.43
In contrast to the study group in the current study, 
patients in the literature review group were more 
likely to have metastases in the extremities (61.9%) 
and to have the lesions discovered due to symptoms. 
Furthermore, metastases were discovered when they 
were relatively large; metastases in this group were 
nearly three times larger in diameter on average than 
those in the study group. It is important to note that 
the apparent average size of metastases in the patients 
from the current study group would have been slightly 
elevated by the exclusion of smaller metastases in the 
two patients with more than eight metastases in total. 
It is possible that the pattern of metastasis location 
and size found among the study cohort was more 
typical of that expected in patients undergoing routine 
follow-up of known RCC, while case reports of RCC in 
the literature tend to describe unusual presentations of 
the condition.
The time interval between the diagnosis of the 
primary tumour and the detection of the muscle 
metastases varied greatly, with several very late 
appearances of metastases. Notably, the calculation of 
intervals in the study group was complicated by four 
patients (one patient presenting with skeletal muscle 
metastasis, one whose skeletal muscle metastases 
were omitted in radiological reports and two who had 
had RCC many years previously before presenting 
with metastatic disease). Many theories have been 
proposed to explain late recurrence of metastatic 
disease, including immunological and hormonal 
factors.10 It is important that radiologists recognise that 
delayed skeletal muscle metastasis of RCC can occur 
so that early diagnosis and intervention are possible, 
particularly because the surgical excision of isolated 
metastases may improve disease-free survival.11,44 
In addition, recent developments in chemotherapy, 
review, was 53.4 mm in the greatest dimension (range: 
10–160 mm).2,10,12–25,27,28,30,32,35,37–40
Of the 14 metastases for which data on CT 
appearance were available, 10 showed enhancement 
and one was isodense to the muscle on non-contrast-
ed CT.7,9,12–18,23 Of the metastases for which data on 
MRI appearance were available, five had low to 
intermediate signal intensity and five had high signal 
intensity on T1-weighted images.2,3,7,10,12,14,17,19,34,35 
Two had intermediate signal intensity and 
nine had high signal intensity on T2-weighted 
images.2,3,7,10,12,14,17,19,30,34,35 One was enhanced with 
contrast administration.2 
Metastases in other organs—mainly the 
lungs and bones—were present at the time of or 
before the initial diagnosis of muscle metastasis 
in 17 of the 29 patients for whom this information 
was specified.2,7,8,10,13,15,19,21,23,24,27,29,32,35,37–39 For 12 
patients, the skeletal muscle metastasis was 
the only known metastasis at the time it was 
discovered.16–18,20,22,25,28,30,31,33,36,40 
Discussion 
The demographic characteristics of patients in both 
the study and literature review groups were relatively 
similar, with an average age of approximately 58 and 
62 years, respectively. There were over six times more 
men than women, with a combined total of eight 
women (14.0%) and 49 men (86.0%). This marked male 
predominance was greater than would be expected 
with regards to population studies that have found 
a male-to-female ratio of less than 2:1 for cases of 
RCC.1,41 Survival rates, which are probably similar to 
metastasis rates, also do not sufficiently differ between 
men and women with RCC to account for this 
male predominance.1
Presentation of skeletal metastases differed 
between the study group and cases from the literature 
review. The former group was distinctly more likely 
to have metastases in the trunk muscles (83.3%) and 
to have metastases discovered by staging studies 
when the lesions were asymptomatic and relatively 
small. These facts are probably related as metastases 
in deep muscles of the trunk (particularly the psoas) 
are not palpable until very large but do lie in the areas 
Schatteman et al.38 2002 1 69/M 24 Trapezius 60 x 30
Shibayama et al.39 1993 1 41/M 34 Tongue muscles 20
Yiotakis et al.40 2001 1 60/M 6 Masseter 15
M = male; N/A = not available; F = female.
*One large mass involving all of these muscles. †Interval between the primary tumour and the discovery of the first skeletal muscle metastasis. ‡Seven 
patients were not included in the analysis due to insufficient details. 
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particularly the use of tyrosine kinase inhibitors, have 
made it possible to treat metastatic RCC, including 
skeletal muscle metastases, with reasonable chances 
of prolonging life.45 To date, two of the patients in 
the study group, both of whom were treated with 
tyrosine kinase inhibitors, have continued to lead 
active lives years after the discovery of their skeletal 
muscle metastases. 
Differentiating skeletal muscle metastases from 
other soft tissue tumours is important because of their 
different treatments and prognosis.4,7 In many cases, 
a biopsy is needed to reach a definitive diagnosis, 
particularly for isolated lesions. Even when a patient 
has multiple metastases, this procedure can be useful 
to find muscle metastases. When several masses are 
present in patients with a known primary tumour, 
generally only one will need to be biopsied. The 
authors of the current study believe that masses in 
skeletal muscle are often fairly superficial and do not 
move during respiration; for these reasons, they may 
therefore be a good option for biopsy. 
Slightly more than half of the patients in the 
literature review group had metastases in other organs 
before or at the time the skeletal muscle metastasis 
was discovered, while all but one of the patients 
in the study group had skeletal muscle metastases 
concomitant with metastasis in other organs. Damron 
et al. reported that RCC metastases in soft tissues, 
including skeletal muscle, almost always present as 
a solitary soft tissue mass after a variable period of 
time from the initial diagnosis of RCC.46 Their view, 
however, was probably influenced by the fact that this 
type of metastatic RCC presentation is preferentially 
described among case reports in the literature as well 
as by the inclusion of their own cases of biopsy-proven 
metastases.46 This inclusion criterion would favour 
isolated metastases because multiple metastases do 
not individually warrant a biopsy. 
In general, skeletal muscle metastases are very 
subtle on non-contrasted CT (isoattenuating to the 
surrounding musculature) and can easily be missed in 
most cases.12 After intravenous contrast administration, 
the most common pattern in the current study group 
was peripheral enhancement. Pretorius et al. found 
rim enhancement in 83% of skeletal muscle metastases 
and Surov et al. found peripheral enhancement in 
32.5% of their cases.6,9 In the current study, some of 
the patients’ skeletal muscle metastases in the study 
group had heterogeneous and homogeneous patterns 
of enhancement with no obvious predominance of one 
over the other; this was similarly described in several 
other reports.2,9,12–19 In contrast, Surov et al. found 
that the homogeneous pattern was the most common, 
with 52.5% of their cases exhibiting homogeneous 
enhancement.6 In the current study, small feeding 
vessels to the skeletal muscle metastases were found 
in a few of the lesions among the study group. This 
feature has been described in previous reports using 
various imaging methods and has been theorised to be 
due to the production of lactic acid by tumours, which 
signals anoxia.2,16,20 New vessels seek out the source of 
anoxia and provide vascularisation.20,47
The MRI signal intensity of the lesions in the 
study group was variable. It was not surprising that 
the signal intensity on T2-weighted images was 
generally higher than that of the surrounding muscle 
and that the lesions generally enhanced with contrast 
administration. Skeletal muscle metastases are usually 
reported to be hypo- to isointense to the muscle on T1-
weighted images, with a small percentage sometimes 
being hyperintense.12,48 Interestingly, however, 71% 
of the muscle metastases with pre-contrast T1-
weighted images in the study group and 50% of those 
in the literature review group were hyperintense 
to surrounding muscle on T1-weighted images. It 
is important to note that none of the patients in the 
study group had a history of melanomas, which may 
be an explanation for the frequency of hyperintense 
T1 lesions among this cohort.
Certain limitations exist with regards to data 
reported from the current study, including the relative 
rarity of MRI studies for patients in the study group. 
Additionally, variable chemotherapy regimens were 
received by the patients, which prevented a meaningful 
study of the effects of specific drugs on the course of 
the disease and any muscle metastasis. Both CT and 
MRI scans were obtained over too long a stretch of 
time using different scan protocols and on various 
types of equipment to allow any meaningful analysis 
of specific imaging parameters. Finally, as this was a 
retrospective study of patients encountered in clinical 
practice and noted in teaching files, the sample was 
affected by selection bias. Despite this, 17 of the 21 
patients presented during a time when information 
was being collected on all cases of skeletal muscle 
metastasis encountered. As a result, those patients 
comprised an essentially consecutive series. Another 
limitation of the current study was that the literature 
review did not identify or include every published case 
of RCC metastatic to skeletal muscle available as it was 
necessary to stop collecting data as of March 2013 and 
perform the analysis. 
Conclusion
The possibility of skeletal muscle metastases should 
always be considered in patients with RCC, even long 
after primary treatment, so as to reduce the chance of 
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from renal cell carcinoma 12 years after nephrectomy: 
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cell carcinoma presenting as a masseteric space mass. 
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0709(97)90011-9.
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- Case report and review of the literature. Urol Int 2009; 
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overlooking skeletal muscle metastases and improve 
staging. Skeletal muscle metastases from RCC may 
be invisible on CT without intravenous contrast, so 
contrast-enhanced studies are recommended for these 
patients. Metastases from RCC are often hyperintense 
to the surrounding muscle on T1-weighted MRIs.
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